Insight on Pharmaceuticals and Healthcare

The following industries match your search criteria:

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Click here to sort results by relevance. Click on heading titles to sort results by different field.

Type Product title / description Pub Price
Report
Report

2009 Pharmaceutical M&A Overview

An overview of M&A trends for the top 150 global pharmaceutical companies during 2008 and 2009 with discussion of the drivers of recent deals, plus case study analysis of key M&As.

Published By Datamonitor
17 Dec 2009 $11400
Buy
Report
Report

Alcon Inc.: PharmaVitae Profile

Analysis of Alcon's corporate strategy, marketed portfolio, pipeline potential and financial position in 2009 and to 2015

Published By Datamonitor
16 Dec 2010 $5700
Buy
Report
Report

Allergan Inc.: PharmaVitae Report

Analysis of Allergan's corporate strategy, marketed portfolio, pipeline potential and financial position in 2010 and to 2016

Published By Datamonitor
09 Dec 2011 $5700
Buy
Report
Report

Apotex Inc.: PharmaVitae Report

Analysis of Apotex's corporate strategy, marketed portfolio and pipeline potential over 2010-2016.

Published By Datamonitor
21 Dec 2011 $5700
Buy
Report
Report

Astellas Pharma Inc.: PharmaVitae Report

Analysis of Astellas's corporate strategy, marketed portfolio, pipeline potential and financial position in 2010 and to 2016

Published By Datamonitor
02 Sep 2011 $3800
Buy
Report
Report

Australia Pharmaceutical Market Overview - Reforms and continued price cuts will change the healthcare landscape

Overview of the Australian pharmaceutical market including socioeconomic and demographic trends, regulatory issues, generics and biosimilars analysis and pharmaceutical company infrastructure analysis.

Published By Datamonitor
29 Jul 2010 $7600
Buy
Report
Report

Autoimmune Market Access in China – New biologic therapies drive future growth

Despite ongoing competition from biosimilars, branded biologics will continue to drive the Chinese autoimmune market, with two new brands, Enbrel (etanercept; Pfizer) and Humira (adalimumab; Abbott), having been approved and launched in 2010.

Published By Datamonitor
14 Sep 2011 $5700
Buy
Report
Report

Bayer AG: Company Analysis

Analysis of Bayer's corporate strategy, marketed portfolio, pipeline potential and financial position in 2011 and to 2017

Published By Datamonitor
08 Aug 2012 $5700
Buy
Report
Report

Big Pharma Mega-Mergers 1995-2014

Revenue and financial performance analysis of the 22 largest Big Pharma M&A events since 1995.

Published By Datamonitor
10 Dec 2009 $7600
Buy
Report
Report

Biosimilars: China Update

Biosimilars: China Update provides analysis on the Chinese biogenerics market. It includes an overview of drivers and resistors to biogeneric uptake, market access strategies, key biogeneric players and future development trends.

Published By Datamonitor
22 Sep 2011 $1900
Buy

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.